Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who have been diagnosed with multiple myeloma, according to standard international diagnostic guidelines
- People who have been diagnosed with primary plasma cell leukemia, according to standard international diagnostic guidelines
- People who have been diagnosed with AL-amyloidosis, according to standard international diagnostic guidelines
- People for whom a doctor has planned treatment with one of the following medicines outside of another clinical trial: Teclistamab (Tecvayli), Elranatamab (Elrexfio), Talquetamab (Talvey), Idecabtagene vicleucel (ide-cel/Abecma), or Ciltacabtagene autoleucel (cilta-cel/Carvykti) — note that which medicines are included may change depending on regulatory approvals in the region (confirm with trial site)
Who may not be able to join:
- No exclusion criteria have been listed for this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +4772825100
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the real-world overall response rates (ORR); Determine real-world progression-free survival (PFS); Determine real-world time-to-next treatment (TTNT); Determine real-world overall survival (OS); Describe the frequency and grading of adverse events of special interest (AESI), defined as described below.; Frequency and grading of all other adverse events occurring during treatment according to CTCAE 5.0 (only grade 3 or higher will be reported).; Describe the microbiological pattern (positive cultures/PCR) of infections during treatment.; Describe the antibiotic resistance pattern of p...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.